Trace amine metabolism in Parkinson's disease: Low circulating levels of octopamine in early disease stages

Neuroscience Letters

Volumn 469, Issue 3, 2010, Pages 348-351

  D'Andrea, Giovanni ^a   Nordera, Gianpietro ^a   Pizzolato, Gilberto ^b   Bolner, Andrea ^a   Colavito, Davide ^c   Flaibani, Raffaella ^d   Leon, Alberta ^c  

^a Villa Margherita Neurology Clinic   (Italy)

^b UNIVERSITY OF TRIESTE   (Italy)

^c Research and Innovation SpA   (Italy)

^d IRCCS SAN CAMILLO HOSPITAL   (Italy)

Author keywords

Noradrenaline; Octopamine; Parkinson disease; Trace amines

Indexed keywords

CARBIDOPA; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; OCTOPAMINE; TYROSINE 3 MONOOXYGENASE; TYROSINE DECARBOXYLASE;

ADULT; AGED; ARTICLE; AUTONOMIC DYSFUNCTION; CONTROLLED STUDY; DISEASE MARKER; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; HYPOSMIA; MAJOR CLINICAL STUDY; MALE; NORADRENALIN BLOOD LEVEL; PARKINSON DISEASE; PRIORITY JOURNAL;

AGED; AMINES; BIOLOGICAL MARKERS; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MIDDLE AGED; NOREPINEPHRINE; OCTOPAMINE; PARKINSON DISEASE; TIME FACTORS;

EID: 73649093368     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neulet.2009.12.025     Document Type: Article

References (25)

1. Axelrod J., and Saavedra J.M. Octopamine: review article. Nature 265 (1977) 501-504
2. Berry M.D., Juorio A.V., Li X.M., and Boulton A.A. Aromatic l-aminoacid decarboxylase: a neglected and misunderstood enzyme. Neurochem. Res. 21 9 (1996) 1075-1087
3. Berry M.D. Mammalian central nervous system trace amines. Pharmacological amphetamines, physiologic neuromodulators. J. Neurochem. 90 (2004) 257-271
4. Borowsky B., Adham N., Jones K.A., Raddatz R., Artymyshyn R., Ogozalek K.L., Durkin M.M., Lakhlani P.P., Bonini J.A., Pathirana S., Boyle N., Pu X., Kouranova E., Lichtblau H., Ochoa F.Y., Branchek T.A., and Gerald C. Trace amines: identification of a family mammalian G protein-coupled receptors. Proc. Natl. Acad. Sci. U.S.A. 98 (2001) 8966-8971
5. Boulton A.A., Jurio A.V., Philips S.R., and Wu P.H. The effect of reserpine and 6-Hydroxydopamine on the concentrations of same arylalkylamines in the rat brain. Br. J. Pharmacol. 59 (1977) 209-214
6. Braak E., Sandmann-Keil D., Rub U., Gai W.P., de Vos R.A., Steur E.N., Arai K., and Braak H. Alpha-synuclein immunopositive parkinson's disease-related inclusion bodies in lower brain stem nuclei. Acta Neuropathol. 101 (2001) 195-201
7. Braak H., Del Tredici K., Bratzke H., Hamm-Clement J., Sandmann-Keil D., and Rüb U. Staging of the intracerebral inclusion body pathology associated with idiopathic Parkinson's disease (preclinical and clinical stages). J. Neurol. 249 Suppl. 3 (2002) III/1-5
8. Burchett S.A., and Hicks T.P. The mysterious trace amines: protean neuromodulators of synaptic transmission in mammalian brain. Prog. Neurobiol. 79 5-6 (2006) 223-246
9. Carlsson T., Carta M., Munoz A., Mattsson B., Winkler C., Kirik D., and Bjorklund A. Impact of serotonin and dopamine neurons on development of L-DOPA-induced dyskinesias in parkinsonian rats is determined by the extent of dopamine neuron degeneration. Brain 132 2 (2009) 319-335
10. Cho S., Duchemin A.M., Neff N.H., and Hadjiconstantinou M. Modulation of tyrosine hydroxylase and aromatic L-amino acid decarboxylase after inhibiting monoamine oxidase-A. Eur. J. Pharmacol. 314 (1996) 51-59
11. D'Andrea G., Terrazzino S., Fortin D., Cocco P., Balbi T., and Leon A. Elusive amines in primary headaches: historical background and prospectives. Neurol. Sci. 24 Suppl. 2 (2003) S65-S67
12. D'Andrea G., Terrazzino S., Fortin D., Farruggio A., Rinaldi L., and Leon A. HPLC electrochemical detection of trace amines and expression of mRNA transcripts of trace amine receptors in circulating leukocytes. Neurosci. Lett. 346 (2003) 89-92
13. D'Andrea G., Terrazzino S., Leon A., Fortin D., Perini F., Granella F., and Bussone G. Elevated levels of circulating trace amines in primary headaches. Neurology 62 (2004) 1701-1705
14. Dyck L.E. Release of same endogenous trace amines from rat striatal slices in the presence and absence of a monoamine oxidase inhibitor. Life Sci. 44 (1989) 1149-1156
15. Federici M., Geracitano R., Tozzi A., Longone P., Di Angelantonio S., Bengtson C.P., Bernardi G., and Mercuri N.B. Trace amines depress GABA A response in dopaminergic neurons by inhibiting G-betagamma-gated inwardly rectifying potassium channels. Mol. Pharmacol. 67 (2005) 1283-1990
16. Garracitano R., Federici M., Prisco S., Bernardi G., and Mercuri N.B. Inhibitory effects of trace amines on rat midbrain dopaminergic neurons. Neuropharmacology 46 (2004) 807-814
17. He H.B., Degan R.J., Wood M., and Wood A.J.J. Optimization of high-performance liquid chromatography assay for catecholamines. Determination of optimal mobile phase composition and elimination of species-dependent differences in extraction recovery of 3,4-dihydroxybenzylamine. J. Chromatogr. 574 (1992) 213-218
18. Ibrahim K.E., Couh M.W., Williams C.W., Fregly M.J., and Migdley J.M. m-Ocotpamine: normal occurrence with p-octopamine in mammalian sympathetic nerves. J. Neurochem. 44 (1985) 1862-1867
19. Jankovic J. Parkinson's disease: clinical features and diagnosis. J. Neurol. Neurosurg. Psych. 79 (2008) 368-376
20. Langston W.J. Parkinson's complex: parkinsonism is just the tip of the iceberg. Ann. Neurol. 59 (2006) 591-596
21. Liberles D.S., and Buck L.B. A second class of chemosensory receptors in the olfactory epithelium. Nature 442 (2006) 645-650
22. Rommelfanger K.S., Edward G.L., Freeman K.G., Liles L.C., Miller G.W., and Weinshenker D. Norepinephrine loss produces more profound motor deficits than MPTP treatment in mice. Proc. Natl. Acad. Sci. U.S.A. 104 34 (2007) 13804-13809
23. Stefani S., Lozano A.M., Peppe A., Stanzione P., Galati S., Tropepi D., Pierantozzi M., Brusa L., Scarnati E., and Mazzone P. Bilateral deep brain stimulation of the peduncolopontine and subthalamic nuclei in severe Parkinson's disease. Brain 130 6 (2007) 1596-1607
24. Stiasny-Kolster K., Doerr Y., Moeller J.C., Höffken H., Behr T.M., Oertel W.H., and Mayer G. Combination of idiopathic REM sleep behavior disorder and olfactory dysfunction as possible indicator for alpha-synucleinopathy demonstrated by dopamine transporter FP-CIT-SPECT. Brain 128 (2005) 126-137
25. Watts R.L., and Coller W.C. Movement Disorders (1997), McGraw-Hill